Scriptaid also impairs CAF’s tumour-supportive properties in vitro and in vivo; thus, Scriptaid or similar HDAC inhibitors may represent a class of molecular therapeutics that target both cancer cells and stromal cells in the microenvironment of solid tumours. The gene discussed is HDAC9; the disease is cancer.